PCRX (Pharmaceuticals) Stock Valuation & Fair Value Fairly valued
PCRX (Pharmaceuticals) trades at a blended P/E of 9.6, about 70% below its historical normal valuation, with a forward growth estimate of 21.2% and a PEG of 0.45. Analysts' one-year estimates have been hit 18% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is PCRX overvalued?
At a blended P/E of 9.6 versus its historical normal P/E of 31.7, PCRX trades about 70% below its typical valuation, with a PEG of 0.45 on 21.2% forward growth. tickerseer currently rates it fairly valued.
What is PCRX's fair value and PEG?
PCRX trades at a blended P/E of 9.6 against a historical normal P/E of 31.7, a PEG of 0.45, and a forward growth estimate of 21.2%.
Has tickerseer's rating of PCRX changed?
tickerseer's rating has been fairly valued since 2026-07-31.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.